Galectin Therapeutics to Present at LD Micro Invitational Conference

May. 28, 2015 7:30 am

NORCROSS, Ga., May 28, 2015 (GLOBE NEWSWIRE) -- Galectin Therapeutics (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announced today that James Czirr, executive chairman, will present a corporate overview and update at the LD Micro Invitational Conference on June 2, 2015, at 4:00 p.m. Pacific time. The conference is being held at the Luxe Sunset Bel Air hotel in Los Angeles.

To listen to the presentation, investors may visit the investor relations section of Galectin Therapeutics' website at An archived audio of the presentation will also be available on Galectin Therapeutics' website for 90 days.

About Galectin Therapeutics

Galectin Therapeutics is developing promising carbohydrate-based therapies for the treatment of fibrotic liver disease and cancer based on the Company's unique understanding of galectin proteins, which are key mediators of biologic function. Galectin seeks to leverage extensive scientific and development expertise as well as established relationships with external sources to achieve cost-effective and efficient development. The Company is pursuing a development pathway to clinical enhancement and commercialization for its lead compounds in liver fibrosis and cancer. Additional information is available at

CONTACT: Galectin Therapeutics Inc.
         Peter G. Traber, M.D.
         President, CEO & CMO
         (678) 620-3186
         Kim Golodetz
         (212) 838-3777

Galectin Therapeutics, Inc. Logo

May 28, 2015 - 7:30 AM EDT

"I work with many of the companies that would be RedChip companies. And we certainly ascribe to the same view that the RedChip Companies do, which is Discovering Tomorrow's Blue Chips Today."

  • Bob McCooey, Senior Vice President, NASDAQ Stock Market